Gayathri Kallukaran is a Junior Journalist with Eastern Eye. She has a Master’s degree in Journalism and Mass Communication from St. Paul’s College, Bengaluru, and brings over five years of experience in content creation, including two years in digital journalism. She covers stories across culture, lifestyle, travel, health, and technology, with a creative yet fact-driven approach to reporting. Known for her sensitivity towards human interest narratives, Gayathri’s storytelling often aims to inform, inspire, and empower. Her journey began as a layout designer and reporter for her college’s daily newsletter, where she also contributed short films and editorial features. Since then, she has worked with platforms like FWD Media, Pepper Content, and Petrons.com, where several of her interviews and features have gained spotlight recognition. Fluent in English, Malayalam, Tamil, and Hindi, she writes in English and Malayalam, continuing to explore inclusive, people-focused storytelling in the digital space.
Imagine a single daily pill that could dramatically cut your risk of heart attacks and strokes. Sounds almost too good to be true, right? Well, scientists from University College London (UCL) believe this vision could soon be a reality. The breakthrough "polypill" combines a statin and three blood pressure-lowering medications, promising to transform how we prevent cardiovascular diseases, one of the UK’s biggest health challenges.
A revolutionary approach to heart disease prevention
Heart disease and strokes are silent killers, claiming thousands of lives each year. The current NHS Health Check programme helps identify at-risk individuals, but the system isn’t reaching nearly enough people. Fewer than half of those eligible even attend their appointments. This means that countless lives could be saved if more people were offered preventive treatment.
That’s where the polypill comes in. Rather than relying on complex risk assessments, UCL experts suggest a much simpler approach: offering the polypill to everyone aged 50 and over. No lengthy health checks, just the pill. This could make it a revolutionary tool in preventing heart attacks and strokes on a massive scale.
What exactly is the polypill?
The polypill is a combination of four well-established drugs: a statin to lower cholesterol and three different blood pressure-lowering medications. The idea of combining these drugs isn’t new; it dates back to a 2003 study that suggested a polypill could prevent up to 80% of heart attacks and strokes in people over 55. Since then, various trials have backed up these claims.
Professor Aroon Hingorani, a leading UCL researcher, explains that most heart attacks and strokes happen in people with “average” risk levels, which means the current system of identifying high-risk individuals often misses the mark. Offering the polypill to everyone over 50 could potentially save far more lives.
A simple, life-saving solution
One of the biggest advantages of the polypill is its simplicity. There’s no need for complicated medical assessments, just a few basic questions to check for side effects. Once that’s done, eligible people can start taking the pill, drastically reducing their risk of heart-related problems.
UCL researchers estimate that even if only 8% of people over 50 take up the offer, the health benefits would far exceed what’s currently achieved through the NHS Health Check. This new approach could make life-saving medication accessible to millions in the same way that vaccines or folic acid fortification do.
Professor Sir Nicholas Wald, another UCL co-author, compares the polypill approach to other public health programmes designed to prevent illness before it happens. “This isn’t about medicalising half the population,” Wald points out. “It’s about making sure people don’t become patients in the first place.”
Affordable, proven, and effective
The polypill is not only effective but also affordable. The medications it contains are all off-patent, meaning they’re inexpensive to produce. Despite the low cost, these drugs have a long-standing track record of success with minimal side effects. In particular, combining three blood pressure drugs at low doses reduces the risk of side effects even further while maximising the benefits.
In 2019, a landmark study in rural Iran showed that taking the polypill for five years reduced heart attacks and strokes by a third. This dramatic finding demonstrates the real-world potential of the polypill to change the game not just in the UK but globally.
What’s next for the polypill?
With such compelling evidence, the next step is figuring out how to introduce the polypill programme nationwide. UCL researchers have proposed a pilot project to evaluate how best to roll it out, looking at factors such as cost, uptake, and long-term effectiveness.
However, for this plan to become a reality, it would require policy changes. Currently, local authorities are required to offer NHS Health Checks, and a polypill programme would need to replace or supplement this. But the UCL team is confident this shift is necessary, calling the current situation “untenable.”
With over seven million people in the UK affected by cardiovascular disease, and more than 200,000 heart attacks and strokes every year, it’s clear that a new approach is desperately needed. The polypill could be that solution: a simple, affordable, and effective way to prevent countless deaths and reduce the burden on the NHS.
A new era in prevention
The polypill isn’t just another medical treatment; it could be the key to unlocking a future with fewer heart attacks and strokes. By offering this life-saving pill to everyone over 50, we could see a drastic reduction in cardiovascular diseases. The scientific evidence is strong, the potential impact is huge, and the time to act is now.
As we wait for further studies and potential rollouts, one thing is certain: prevention is always better than cure, and the polypill could very well be the future of heart disease prevention.
How noticing the changes in my father taught me the importance of early action, patience, and love
I don’t understand people who don’t talk or see their parents often. Unless they have done something to ruin your lives or you had a traumatic childhood, there is no reason you shouldn’t be checking in with them at least every few days if you don’t live with them.
Earlier this year, I had the privilege of looking after my parents – they lived with me while their old house was being sold, and their new house was being renovated.
Within this time, I noticed things happening to my dad (Chamanlal Mulji), an 81-year-old retired joiner. Dad was known as Simba when he lived in Zanzibar, East Africa because he was like a lion. A man in fairly good health, despite being an ex-smoker, he’d only had heart surgery back in 2017. In the last few years, he was having some health issues, but certain things, like his walking and driving becoming slow, and his memory failing, we just put down to old age. Now, my dad was older than my friend’s dad. Many of whom in their 70’s, dad, at 81 was an older dad, not common back in the seventies when he married my mum.
It was only when I spent extended time around my parents that I started noticing that certain things weren’t just due to old age. Some physical symptoms were more serious, but certain things like forgetting that the front door wasn’t the bathroom door, and talking about old memories thinking that they had recently happened rang alarm bells for me and I suspected that he might have dementia.
Dementia generally happens in old age when the brain starts to shrink. Someone described it to me as a person’s brain being like a bookshelf. The books at the top of the shelf are the new memories and the books at the bottom are the new memories. The books at the top have fallen off, leaving only the old memories being remembered. People with dementia are also highly likely to suffer from strokes.
Sadly, my dad was one of the few that suffered a stroke and passed away on 28th June 2025. If you have a parent, family member or anyone you know and you suspect that they might have dementia, please talk to your GP straight away. Waiting lists within the NHS are extremely LONG so the quicker people with dementia are treated, the better. Sadly, the illness cannot be reversed but medication can help it from getting worse.
One thing I would also advise is to have patience. Those suffering with dementia can be agitated and often become aggressive, but that’s only because they’re frustrated that they cannot do things the way they used to.
The disease might hide the person underneath, but there’s still a person in there who needs your love and attention.” - Jamie Calandriello
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.
Eli Lilly has agreed a discounted supply deal for its weight-loss drug Mounjaro
Eli Lilly had announced a steep price rise of up to 170% for Mounjaro.
A new discount deal with UK suppliers will limit the increase for patients.
Pharmacies will still apply a mark-up, but consumer costs are expected to rise less than initially feared.
NHS pricing remains unaffected due to separate arrangements.
Eli Lilly has agreed a discounted supply deal for its weight-loss drug Mounjaro, easing fears of a sharp rise in costs for UK patients. The new arrangement means that, from September, pharmacies and private services will face smaller wholesale increases than first expected, limiting the impact on consumers.
Why the price rise was announced
Earlier this month, Eli Lilly said it would raise Mounjaro’s list price by as much as 170%, which could have pushed the highest monthly dose from £122 to £330. The company argued that UK pricing needed to align more closely with higher costs in Europe and the United States.
Discount deal for UK suppliers
The revised agreement will see the top-dose price set at £247.50 for suppliers. While pharmacies and private providers will still add their own margins, the increase for patients is now likely to remain under 50% for higher doses, and even lower for smaller doses.
Eli Lilly confirmed:
“We are working with private providers on commercial arrangements to maintain affordability and expect these to be passed onto patients when the change is effective on 1 September.”
Impact on consumers
Around 1.5 million people in the UK are currently on weight-loss drugs, with more than half using Mounjaro. Most of these patients—around 90%—pay privately through online services or high street pharmacies.
Prices vary between providers, depending on the level of lifestyle and dietary support offered alongside the injections.
Olivier Picard of the National Pharmacy Association said:
“This rebate will mitigate some of the impact of the increase, but patients should still anticipate seeing a rise in prices from 1 September.”
NHS pricing unchanged
The deal does not affect the NHS, which has secured its own heavily-discounted price for patients prescribed the weekly injection.
Mounjaro works by helping patients feel fuller for longer, reducing food intake and supporting weight loss of up to 20% of body weight.
Keep ReadingShow less
The Department of Health said the rollout would reduce missed days at nursery and school, cut time parents take off work, and save the NHS about £15 million a year. (Representational image: iStock)
CHILDREN in England will be offered a free chickenpox vaccine for the first time from January 2026, the government has announced.
GP practices will give eligible children a combined vaccine for measles, mumps, rubella and varicella (MMRV) as part of the routine childhood vaccination schedule. Around half a million children each year are expected to be protected.
The Department of Health said the rollout would reduce missed days at nursery and school, cut time parents take off work, and save the NHS about £15 million a year. Research estimates chickenpox in childhood leads to £24 million in lost income and productivity annually.
Minister of State for Care, Stephen Kinnock, said: “We’re giving parents the power to protect their children from chickenpox and its serious complications, while keeping them in nursery or the classroom where they belong and preventing parents from scrambling for childcare or having to miss work. This vaccine puts children’s health first and gives working families the support they deserve. As part of our Plan for Change, we want to give every child the best possible start in life, and this rollout will help to do exactly that.”
Dr Gayatri Amirthalingam, Deputy Director of Immunisation at the UK Health Security Agency, said: “Most parents probably consider chickenpox to be a common and mild illness, but for some babies, young children and even adults, chickenpox can be very serious, leading to hospital admission and tragically, while rare, it can be fatal. It is excellent news that from next January we will be introducing a vaccine to protect against chickenpox into the NHS routine childhood vaccination programme – helping prevent what is for most a nasty illness and for those who develop severe symptoms, it could be a life saver.”
Amanda Doyle, National Director for Primary Care and Community Services at NHS England, said: “This is a hugely positive moment for families as the NHS gets ready to roll out a vaccine to protect children against chickenpox for the first time, adding to the arsenal of other routine jabs that safeguard against serious illness.”
The eligibility criteria will be set out in clinical guidance, and parents will be contacted by their GP surgery if their child is eligible.
WHEN broadcaster and journalist Naga Munchetty began speaking openly about her experiences with adenomyosis and debilitating menstrual pain, the response was overwhelming.
Emails and messages poured in from women who had endured years of dismissal, silence and shame when it came to their health. That outpouring became the driving force behind her new book, It’s Probably Nothing, which calls for women to be heard and to advocate for themselves in a medical system that has too often ignored them.
“For so long, so many women haven’t been listened to by the world of medicine,” Munchetty said. “I knew this from my own experience of not being given adequate pain relief, or waiting years for a diagnosis. My motivation was to help women and people who love women to advocate better for women’s health.”
The book blends Munchetty’s personal journey with the voices of other women who have faced similar struggles, alongside expert insights from medical professionals. Its purpose, she said, is clear: to empower people to fight for their health.
“We need to be unafraid of saying how we have been weakened by our symptoms,” the BBC presenter said.
“Too often, we try to keep afloat, keep our head above water, but we don’t want to seem weak. That needs to change.”
Munchetty’s candour is striking. She describes the shame of being told her excruciating periods were “just normal,” leaving her to feel weak and whiny for struggling.
“You might as well have told me people have heart attacks while I’m having a heart attack,” she said. “Debilitating pain is serious — it may not be lifelimiting, but it is life-impacting.”
Her determination to challenge that culture led to her giving evidence in parliament, contributing to what became a Women and Equalities Committee report, published in December 2024.
The report made headlines for its stark conclusion: medical misogyny exists.
For Munchetty, seeing that phrase in black and white was transformative. “It was almost self-affirming,” she said. “We now know it’s there, so we can challenge it. Women can say: I know my body, I know there’s not enough research, and I am entitled to push for answers.”
The parliamentary report went further than acknowledgement. It called for ring-fenced funding for women’s health hubs, better training for GPs, and greater investment in research into reproductive conditions like adenomyosis and endometriosis.
It highlighted how symptoms are routinely dismissed as “normal,” delaying diagnosis and disrupting women’s careers, education and daily lives. Munchetty wrote in her book — referencing the report — that medical misogyny is not about blaming individual doctors, but about challenging a system built on insufficient research into women’s bodies.
“It gives women the language and the confidence to not just be heard, but to insist on being taken seriously,” she wrote.
Her book also tackles the additional barriers faced by women from minority communities, who may be discouraged by stigma or embarrassment from speaking about menstruation or menopause. To them, Munchetty has a clear message: “You are so much more valuable than you realise. If you don’t prioritise your health, you are lessening your ability to hold up everyone around you.”
Those featured in the book are friends, colleagues, charities and everyday women who contributed their stories, many for the first time. “I was surprised at how many friends are in that book with such powerful experiences,” Munchetty said.
“It told me all the more that we’re not speaking about it, and that it is sadly so very common.”
At a launch event for the book, contributors, family and experts filled the room with what Munchetty describes as an “electric and inspiring atmosphere.”
She said, “It was full of joy, of women who felt safe to speak up and be heard. This is not a whiny book — it’s a positive book. People felt they were part of making things better, part of this women’s health revolution.”
For Munchetty, writing the book was exhausting, but transformative, she said.
“I never thought I’d be an author. I’m a journalist. But this is journalism — facilitating people’s stories to be told powerfully and truthfully. People trusted me, and I’m proud of that.”
And Munchetty’s aim is for the book to be a tool for change: arming women with the language, confidence and strategies to advocate for their health.
“It’s not easy to admit you need help, and it’s not instinctive for women to prioritise themselves,” she said. “But this book will help you do that. It’s the silent friend who has your back and gives you strength.”
It’s Probably Nothing - Critical Conversations on the Women’s Health Crisis is now available in all good bookshops
Keep ReadingShow less
Williams explained that her weight challenges began after the birth of her first daughter
Serena Williams reveals she has lost more than 31lbs using a GLP-1 medication
The tennis legend says the treatment enhanced her existing healthy lifestyle
She stresses that weight loss should not change self-image or self-confidence
Serena Williams has revealed she has lost more than 31lbs after turning to a weight-loss medication, saying the treatment has transformed both her body and her mindset.
The 23-time Grand Slam champion, 43, told PEOPLE that using a GLP-1 medication — a type of injection that works by regulating appetite — has helped enhance the healthy lifestyle she already maintained through diet and exercise.
“I feel great,” Williams said. “I feel really good and healthy. I feel light physically and light mentally.”
Postpartum struggles
Williams explained that her weight challenges began after the birth of her first daughter, Alexis Olympia, in 2017. Despite training intensively and eating healthily, she found it difficult to return to her preferred weight.
“I never was able to get to the weight I needed to be, no matter what I did, no matter how much I trained,” she admitted. “It was frustrating to work so hard and not see results.”
She experienced the same plateau after giving birth to her second daughter, Adira River, in 2023. Although she initially shed weight quickly, progress soon stalled. “I never lost another pound,” she recalled.
Turning to treatment
Determined to try a new approach, Williams consulted doctors through Ro, a direct-to-patient healthcare company, and began a GLP-1 course once she had finished breastfeeding. The medication, also known as a glucagon-like peptide-1 receptor agonist, is commonly marketed under brand names such as Ozempic and Mounjaro.
“I did a lot of research before I started,” she explained. “I wanted to know if it was a shortcut or if it could really help me. In the end, it felt like the right decision.”
Williams, who is now a patient ambassador for Ro, said the injections made a noticeable difference. “I lost over 31 pounds and was really excited about that weight loss.”
Feeling better than ever
The Olympic gold medallist says she now feels stronger and more energetic.
“I can do more. I’m more active. My joints don’t hurt as much. Even simple things like moving around are easier. I feel like I have a lot more energy.”
She emphasised that GLP-1 was not a substitute for discipline but a way to support her existing healthy habits. “GLP-1 helped me enhance everything I was already doing — eating healthy and working out, whether as a professional athlete or just at the gym every day.”
Confidence and body positivity
Despite her transformation, Williams stressed that her self-confidence has never depended on her size.
“Weight loss should never really change your self-image,” she said. “Women are judged about their bodies at any size, and I’m no stranger to that. I’ve always loved myself at every stage. The difference was that my body didn’t feel good carrying that extra weight after having children.”
She added that she encourages her daughters to embrace body confidence too. “It’s important to teach them to be confident at any size, just as I try to be. Looking back, whether I was smaller or heavier, I always felt confident — and I looked great too.”
Looking ahead
Williams says she plans to continue with the weekly GLP-1 injections as needed, alongside training for a half marathon. The gym remains her “favourite place to be” — and she intends to keep sharing her workouts with fans online.